Biodexa Pharmaceuticals annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals R&D Spending Growth & History (BDRX)
Biodexa Pharmaceuticals's r&d spending was £4.0M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £4.0M | −£1.5M | −27.15% |
| 2024 | 2024-12-31 | £5.4M | £1.4M | +33.69% |
| 2023 | 2023-12-31 | £4.1M | −£1.0M | −20.43% |
| 2022 | 2022-12-31 | £5.1M | £457,000 | +9.82% |
| 2021 | 2021-12-31 | £4.7M | −£1.4M | −23.30% |
| 2020 | 2020-12-31 | £6.1M | −£1.8M | −22.63% |
| 2019 | 2019-12-31 | £7.8M | −£1.5M | −16.20% |
| 2018 | 2018-12-31 | £9.4M | £1.0M | +12.37% |
| 2017 | 2017-12-31 | £8.3M | £599,000 | +7.75% |
| 2016 | 2016-12-31 | £7.7M | −£980,000 | −11.25% |
| 2015 | 2015-12-31 | £8.7M | — | — |
Biodexa Pharmaceuticals r&d spending trends
Over the last five fiscal years, Biodexa Pharmaceuticals's r&d spending decreased from £6.1M to £4.0M, a change of −£2.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...